These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

251 related items for PubMed ID: 24598841

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Serum hepcidin measured with an improved ELISA correlates with parameters of iron metabolism in patients with myelodysplastic syndrome.
    Zipperer E, Post JG, Herkert M, Kündgen A, Fox F, Haas R, Gattermann N, Germing U.
    Ann Hematol; 2013 Dec; 92(12):1617-23. PubMed ID: 23842708
    [Abstract] [Full Text] [Related]

  • 5. Iron overload across the spectrum of non-transfusion-dependent thalassaemias: role of erythropoiesis, splenectomy and transfusions.
    Porter JB, Cappellini MD, Kattamis A, Viprakasit V, Musallam KM, Zhu Z, Taher AT.
    Br J Haematol; 2017 Jan; 176(2):288-299. PubMed ID: 27917462
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Growth differentiation factor 15 is related to anemia and iron metabolism in heart allograft recipients and patients with chronic heart failure.
    Przybyłowski P, Wasilewski G, Bachorzewska-Gajewska H, Golabek K, Dobrzycki S, Małyszko J.
    Transplant Proc; 2014 Oct; 46(8):2852-5. PubMed ID: 25380934
    [Abstract] [Full Text] [Related]

  • 9. Dyserythropoiesis evaluated by the RED score and hepcidin:ferritin ratio predicts response to erythropoietin in lower-risk myelodysplastic syndromes.
    Park S, Kosmider O, Maloisel F, Drenou B, Chapuis N, Lefebvre T, Karim Z, Puy H, Alary AS, Ducamp S, Verdier F, Bouilloux C, Rousseau A, Jacob MC, Debliquis A, Charpentier A, Gyan E, Anglaret B, Leyronnas C, Corm S, Slama B, Cheze S, Laribi K, Amé S, Rose C, Lachenal F, Toma A, Pica GM, Carre M, Garban F, Mariette C, Cahn JY, Meunier M, Herault O, Fenaux P, Wagner-Ballon O, Bardet V, Dreyfus F, Fontenay M.
    Haematologica; 2019 Mar; 104(3):497-504. PubMed ID: 30287621
    [Abstract] [Full Text] [Related]

  • 10. Regulation of iron metabolism through GDF15 and hepcidin in pyruvate kinase deficiency.
    Finkenstedt A, Bianchi P, Theurl I, Vogel W, Witcher DR, Wroblewski VJ, Murphy AT, Zanella A, Zoller H.
    Br J Haematol; 2009 Mar; 144(5):789-93. PubMed ID: 19120353
    [Abstract] [Full Text] [Related]

  • 11. The evaluation of iron overload through hepcidin level and its related factors in myelodysplastic syndromes.
    Gu S, Song X, Zhao Y, Guo J, Fei C, Xu F, Wu L, Zhang X, Zhao J, Chang C, Li X.
    Hematology; 2013 Sep; 18(5):286-94. PubMed ID: 23540794
    [Abstract] [Full Text] [Related]

  • 12. Iron Status in Newly Diagnosed β-Thalassemia Major: High Rate of Iron Status due to Erythropoiesis Drive.
    Susanah S, Rakhmilla LE, Ghozali M, Trisaputra JO, Moestopo O, Sribudiani Y, Idjradinata PS, Maskoen AM.
    Biomed Res Int; 2021 Sep; 2021():5560319. PubMed ID: 33954177
    [Abstract] [Full Text] [Related]

  • 13. Hepcidin and diabetes are independently related with soluble transferrin receptor levels in chronic dialysis patients.
    Belo L, Rocha S, Valente MJ, Coimbra S, Catarino C, Bronze-da-Rocha E, Rocha-Pereira P, do Sameiro-Faria M, Oliveira JG, Madureira J, Fernandes JC, Miranda V, Santos-Silva A.
    Ren Fail; 2019 Nov; 41(1):662-672. PubMed ID: 31296086
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Erythropoiesis and Iron Homeostasis in Non-Transfusion-Dependent Thalassemia Patients with Extramedullary Hematopoiesis.
    Huang Y, Liu R, Wei X, Liu J, Pan L, Yang G, Lai Y.
    Biomed Res Int; 2019 Nov; 2019():4504302. PubMed ID: 30834265
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Labile plasma iron levels predict survival in patients with lower-risk myelodysplastic syndromes.
    de Swart L, Reiniers C, Bagguley T, van Marrewijk C, Bowen D, Hellström-Lindberg E, Tatic A, Symeonidis A, Huls G, Cermak J, van de Loosdrecht AA, Garelius H, Culligan D, Macheta M, Spanoudakis M, Panagiotidis P, Krejci M, Blijlevens N, Langemeijer S, Droste J, Swinkels DW, Smith A, de Witte T, EUMDS Steering Committee.
    Haematologica; 2018 Jan; 103(1):69-79. PubMed ID: 29122992
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [Myelodysplastic syndromes and iron metabolism].
    Kawabata H.
    Rinsho Ketsueki; 2018 Jan; 59(10):2042-2049. PubMed ID: 30305507
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.